Product Description
Eli Lilly is developing LY-3454738 as a treatment for atopic dermatitis (eczema). (Sourced from: https://trials.lilly.com/en-US/trial/283580)
Mechanisms of Action: CD200 Agonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, Hungary, Italy, Japan, Korea, Mexico, Poland, Puerto Rico, Taiwan, United States, Unknown Location
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Dermatitis, Atopic
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2031230201 | P2 |
Not yet recruiting |
Dermatitis, Atopic |
2025-12-31 |
|
| J4E-MC-FR01 | P2 |
Recruiting |
Dermatitis, Atopic |
2024-09-16 |
24% |
| J1B-MC-FRCJ | P1 |
Active, not recruiting |
Healthy Volunteers |
2024-05-02 |
28% |
| J1B-MC-FRCC | P1 |
Completed |
Dermatitis, Atopic |
2021-09-07 |
21% |